Biogen Idec, Inc. (BIIB) Tops Q3 Adj-EPS by 8c
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $220.83 --0%
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +4.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 4.71
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q3 EPS of $1.61, ex-items, $0.08 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.27 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $245 at Piper Sandler
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
